We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Skin in the game

26 Aug 2019 By Richard Beales

The drugmaker is stretching to buy ​rival Celgene. To smooth U.S. antitrust review, it put its target’s blockbuster psoriasis treatment on the market. Amgen has won that prize, for an unexpectedly rich $13 bln. That’s a boost for Bristol-Myers’ deal rationale – and its timing.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)